Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Boxer Capital Management, Llc Sells 625,000 Shares

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Boxer Capital Management, Llc sold 625,000 shares of the firm’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $7.05, for a total transaction of $4,406,250.00. Following the transaction, the insider now directly owns 7,573,642 shares of the company’s stock, valued at approximately $53,394,176.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tango Therapeutics Stock Performance

Shares of Tango Therapeutics stock traded down $0.37 on Wednesday, hitting $6.27. The company’s stock had a trading volume of 881,138 shares, compared to its average volume of 762,270. The company has a market capitalization of $669.92 million, a price-to-earnings ratio of -5.55 and a beta of 0.81. The firm has a fifty day moving average price of $8.85 and a 200-day moving average price of $8.49. Tango Therapeutics, Inc. has a 1 year low of $6.12 and a 1 year high of $13.01.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.10. Tango Therapeutics had a negative return on equity of 44.73% and a negative net margin of 274.04%. The business had revenue of $19.88 million during the quarter, compared to analysts’ expectations of $7.39 million. As a group, analysts forecast that Tango Therapeutics, Inc. will post -1.27 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of Tango Therapeutics in a research report on Tuesday, September 10th. Jefferies Financial Group began coverage on Tango Therapeutics in a research note on Wednesday, July 17th. They issued a “buy” rating and a $19.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Tango Therapeutics in a research report on Tuesday, July 9th. Finally, Wedbush boosted their price target on Tango Therapeutics from $11.00 to $13.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $15.14.

Hedge Funds Weigh In On Tango Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its holdings in shares of Tango Therapeutics by 110.8% during the fourth quarter. Wellington Management Group LLP now owns 170,228 shares of the company’s stock valued at $1,685,000 after acquiring an additional 89,481 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Tango Therapeutics by 32.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company’s stock valued at $230,000 after acquiring an additional 7,128 shares in the last quarter. SG Americas Securities LLC raised its holdings in Tango Therapeutics by 16.0% in the 1st quarter. SG Americas Securities LLC now owns 30,429 shares of the company’s stock valued at $242,000 after acquiring an additional 4,203 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in Tango Therapeutics in the 1st quarter worth approximately $272,000. Finally, Vanguard Group Inc. lifted its stake in Tango Therapeutics by 3.4% in the 1st quarter. Vanguard Group Inc. now owns 3,080,885 shares of the company’s stock worth $24,462,000 after purchasing an additional 101,673 shares in the last quarter. 78.99% of the stock is currently owned by institutional investors and hedge funds.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.